Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

495
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
495
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

JCO oncology practice·2026
Same author

International Survey and NGS-Based Indel Chimerism Detection of HLA Loss in Relapsed Haploidentical andMismatched Unrelated Donor Transplant Recipients.

Transplantation and cellular therapy·2026
Same author

Reconsidering the role of bone marrow as a graft source in haploidentical allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2026
Same author

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026
Same author

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.

The New England journal of medicine·2026
Same author

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

The Lancet. Haematology·2026
Same journal

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance.

Current hematologic malignancy reports·2026
Same journal

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Current hematologic malignancy reports·2026
Same journal

Germline DDX41 Variants: Current Understanding and Future Directions.

Current hematologic malignancy reports·2026
Same journal

Clonal Signatures of Telomere Biology Disorders.

Current hematologic malignancy reports·2026
Same journal

Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.

Current hematologic malignancy reports·2026
Same journal

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes.

Current hematologic malignancy reports·2026
See all related articles

Related Experiment Video

Updated: Sep 11, 2025

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.7K

Allogeneic Transplant for CMML.

Nico Gagelmann1, Nihar Desai2,3

  • 1Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. nico.gagelmann@posteo.de.

Current Hematologic Malignancy Reports
|August 11, 2025
PubMed
Summary
This summary is machine-generated.

Allogeneic hematopoietic cell transplantation (allo-HCT) is a key treatment for chronic myelomonocytic leukemia (CMML). Individualized transplant timing and optimized strategies significantly improve outcomes and life expectancy for CMML patients.

More Related Videos

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.1K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K

Related Experiment Videos

Last Updated: Sep 11, 2025

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.7K
Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.1K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Chronic myelomonocytic leukemia (CMML) is a rare hematologic malignancy.
  • It bridges myelodysplastic (MDS) and myeloproliferative neoplasms, primarily affecting older adults.
  • Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative option but is limited by patient age and comorbidities.

Purpose of the Study:

  • To review the evolving management of CMML.
  • To highlight the critical role of allo-HCT in CMML treatment.
  • To discuss advancements in patient stratification and transplant optimization.

Main Methods:

  • Review of recent studies and clinical data on CMML management.
  • Analysis of factors influencing allo-HCT outcomes.
  • Evaluation of novel therapeutic strategies and prognostic tools.

Main Results:

  • Individualized transplant timing significantly improves life expectancy in CMML patients.
  • Optimizing outcomes requires managing splenomegaly, debulking, donor selection, and conditioning regimens.
  • Treosulfan-based and thiotepa-busulfan regimens show favorable toxicity and relapse profiles.
  • Post-transplant strategies like PTCy and MRD monitoring refine patient management.
  • Innovative therapies are under investigation to improve pre- and post-transplant outcomes.

Conclusions:

  • Advancements in molecular classification and prognostic tools are reshaping CMML treatment.
  • Personalized approaches integrating genetic risk, fitness, and disease characteristics enhance transplant strategies.
  • The ultimate goal is to extend survival and improve quality of life for CMML patients.